Prevention of glucocorticoid-induced osteoporosis: Provider practice at an urban county hospital

被引:41
作者
Aagaard, EM
Lin, P
Modin, GW
Lane, NE
机构
[1] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA 94010 USA
[2] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94010 USA
[3] San Francisco Gen Hosp, San Francisco, CA 94110 USA
关键词
D O I
10.1016/S0002-9343(99)00265-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: We sought to determine the frequency and types of prophylaxis for osteoporosis that were prescribed to outpatients who were receiving chronic glucocorticoid treatment and to identify the patient and provides characteristics that were associated with the use of prophylaxis. SUBJECTS AND METHODS: We identified 215 adult outpatients at San Francisco General Hospital who had received a prescription for prednisone (or its equivalent) at a daily dose of at least 5 mg for at least 1 month. Patient demographic characteristics, the diagnosis for which glucocorticoids were prescribed, comorbid illnesses, and medications were determined by chart review. Characteristics of the patients who were prescribed prophylaxis were compared with those of patients who were not prescribed prophylaxis. RESULTS: Prophylaxis for glucocorticoid-induced osteoporosis was prescribed to 58% of patients. Patients prescribed prophylaxis were older (mean [+/- SD] age of 50.0 +/- 13.9 versus 44.5 +/- 13.6 years, P = 0.004), more likely to be female (69% versus 40%, P <0.0001), postmenopausal if female (84% versus 56%, P = 0.002), have more comorbid illnesses (63% versus 29%, P = 0.001), and take multiple medications (66% versus 45%, P = 0.002). Patients attending the rheumatology clinic were 1.6 times more likely to receive prophylaxis than those attending other clinics (P <0.0001). The strongest predictor of prophylaxis was postmenopausal state. In premenopausal women, the independent predictors of prophylaxis were being treated in the rheumatology clinic and the presence of comorbid illnesses, whereas comorbid illnesses was the only independent predictor of prophylaxis in men. CONCLUSIONS: Educational efforts should be directed toward increasing awareness of the importance of glucocorticoid-induced osteoporosis and its prevention. Am J Med. 1999;107: 456-460. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:456 / 460
页数:5
相关论文
共 39 条
  • [1] Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
    Adachi, JD
    Bensen, WG
    Brown, J
    Hanley, D
    Hodsman, A
    Josse, R
    Kendler, DL
    Lentle, B
    Olszynski, W
    SteMarie, LG
    Tenenhouse, A
    Chines, AA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) : 382 - 387
  • [2] ADACHI JD, 1994, J RHEUMATOL, V21, P1922
  • [3] STEROID-INDUCED FRACTURES AND BONE LOSS IN PATIENTS WITH ASTHMA
    ADINOFF, AD
    HOLLISTER, JR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (05) : 265 - 268
  • [4] Calcium and vitamin D-3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis - A randomized, double-blind, placebo-controlled trial
    Buckley, LM
    Leib, ES
    Cartularo, KS
    Vacek, PM
    Cooper, SM
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (12) : 961 - +
  • [5] CLEGG D O, 1983, Arthritis and Rheumatism, V26, pS47
  • [6] RHEUMATOID-ARTHRITIS, CORTICOSTEROID-THERAPY AND HIP FRACTURE
    COOPER, C
    COUPLAND, C
    MITCHELL, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (01) : 49 - 52
  • [7] Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women
    Cundy, T
    Farquhar, CM
    Cornish, J
    Reid, IR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) : 1014 - 1017
  • [8] CYCLICAL ETIDRONATE PLUS ERGOCALCIFEROL PREVENTS GLUCOCORTICOID-INDUCED BONE LOSS IN POSTMENOPAUSAL WOMEN
    DIAMOND, T
    MCGUIGAN, L
    BARBAGALLO, S
    BRYANT, C
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 98 (05) : 459 - 463
  • [9] PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPENIA - EFFECT OF ORAL 25-HYDROXYVITAMIN-D AND CALCIUM
    DIMUNNO, O
    BEGHE, F
    FAVINI, P
    DIGIUSEPPE, P
    PONTRANDOLFO, A
    OCCHIPINTI, G
    PASERO, G
    [J]. CLINICAL RHEUMATOLOGY, 1989, 8 (02) : 202 - 207
  • [10] EFFECT OF ORAL 1,25-DIHYDROXYVITAMIN-D AND CALCIUM ON GLUCOCORTICOID-INDUCED OSTEOPENIA IN PATIENTS WITH RHEUMATIC DISEASES
    DYKMAN, TR
    HARALSON, KM
    GLUCK, OS
    MURPHY, WA
    TEITELBAUM, SL
    HAHN, TJ
    HAHN, BH
    [J]. ARTHRITIS AND RHEUMATISM, 1984, 27 (12): : 1336 - 1343